Cytori Therapeutics, Inc.Tiago Girao, Chief Financial Officer, 1.858.458.0900
Cytori Therapeutics, Inc. (NASDAQ: CYTX) has been selected to participate in a U.S. trade mission to Japan and South Korea led by the U.S. Secretary of Commerce Penny Pritzker. The business development mission to be conducted this month involves 20 companies in the health care and energy sectors. Cytori is uniquely positioned as a leading regenerative medicine company to contribute meaningfully to the dialogue between the U.S. sectors and leaders in Japan and South Korea.
The goal of Secretary Pritzker’s first trade mission to Asia is to promote U.S. exports to Japan and South Korea by helping American companies launch or increase their business in these key markets. The Cytori delegation will include Mr. Kenneth Kleinhenz, Vice President of Global Regulatory Affairs and Mr. Seijiro Shirahama, President of Asia Pacific. Mr. Kleinhenz has led the ongoing collaboration with local trade groups, the medical device community and the government of Japan on its newly proposed regenerative medicine law to be finalized later next month.
For more information about the trade mission, please visit
Cytori Therapeutics, Inc. is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. Our scientific data suggest ADRCs improve blood flow, moderate the immune response and keep tissue at risk of dying alive. As a result, we believe these cells can be applied across multiple “ischemic” conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori's proprietary technologies and products, including the Celution® system product family. For more information visit .